Gene · 3073
Papers1,522
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 1,522
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Spectrum of Genetic Mutations Among Iranian Patients with Gangliosidosis. | Biochem Genet | 2026 | 40172712 | PubTator, text mining | PubMed |
| Targeted lipidomics meets transcriptomics: how cinobufagin rewires fatty acid, sphingolipid, and glycerophospholipid metabolism to combat hepatoma cell growth. | Front Pharmacol | 2025 | 41737012 | PubTator, text mining | PubMed |
| Mass spectrometric profiling reveals alterations in N-Glycans and O-Glycans in Tay-Sachs disease under Autophagy-Induced conditions. | Glycoconj J | 2025 | 41460292 | PubTator, text mining | PubMed |
| mRNA Isoforms and Variants in Health and Disease. | Int J Mol Sci | 2025 | 41096623 | PubTator, text mining | PubMed |
| Engineering of BZ transposase and transposon donor vector for enhanced efficiency and safety in gene delivery applications. | Nucleic Acids Res | 2025 | 40985774 | PubTator, text mining | PubMed |
| Impact of charcoal production on soil micronutrients, enzyme activities, microbial composition, and biomass phosphorus in a derived savannah ecosystem of Nigeria. | Sci Rep | 2025 | 40890468 | PubTator, text mining | PubMed |
| Generation of three human induced pluripotent stem cell (hiPSC) lines from patients with Late-Onset Tay-Sachs disease (HEXA-related adult-onset GM2-gangliosidosis). | Stem Cell Res | 2025 | 40819571 | PubTator, text mining | PubMed |
| Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial. | Nat Med | 2025 | 40817303 | PubTator, text mining | PubMed |
| Alpha-synuclein inclusions reduced by PIKfyve inhibition in Parkinson disease cell models. | Neurobiol Dis | 2025 | 40812540 | PubTator, text mining | PubMed |
| Lysosomal free sialic acid storage disorder iPSC-derived neural cells display altered glycosphingolipid metabolism. | Sci Rep | 2025 | 40804080 | PubTator, text mining | PubMed |
| Quantifying Hydrolytic Enzymes in the Vitreous Humor of Humans and Nonhuman Species Using Targeted Proteomics. | J Proteome Res | 2025 | 40783862 | PubTator, text mining | PubMed |
| Challenges and innovations in resistance, remediation, and regulation: key findings from the spring 2025 ASM Theobald Smith Society meeting. | mSphere | 2025 | 40757849 | PubTator, text mining | PubMed |
| NetTCR-struc, a structure driven approach for prediction of TCR-pMHC interactions. | Front Immunol | 2025 | 40746534 | PubTator, text mining | PubMed |
| Emerging trends in prime editing for precision genome editing. | Exp Mol Med | 2025 | 40744998 | PubTator, text mining | PubMed |
| Advances in Diagnosis, Pathological Mechanisms, Clinical Impact, and Future Therapeutic Perspectives in Tay-Sachs Disease. | Neurol Int | 2025 | 40710901 | PubTator, text mining | PubMed |
| Exploring hypoxia-related genes in spinal cord injury: a pathway to new therapeutic targets. | Front Mol Neurosci | 2025 | 40462837 | PubTator, text mining | PubMed |
| Molecular genetic analysis of pulmonary benign metastasizing leiomyoma and intravenous leiomyomatosis: a comparative study using whole exome sequencing. | Discov Oncol | 2025 | 40434516 | PubTator, text mining | PubMed |
| Evaluation of the PP6D5 Polymer as a Novel Non-Viral Vector in the Development of a CRISPR/nCas9-Based Gene Therapy for Tay-Sachs Disease. | Pharmaceutics | 2025 | 40430919 | PubTator, text mining | PubMed |
| Yeast-Produced Human Recombinant Lysosomal β-Hexosaminidase Efficiently Rescues GM2 Ganglioside Accumulation in Tay-Sachs Disease. | J Pers Med | 2025 | 40423067 | PubTator, text mining | PubMed |
| Decoding the Liver-Heart Axis in Cardiometabolic Diseases. | Circ Res | 2025 | 40403112 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3073/papers?page=2